Sugi Predict

Sugi Predict / Compounds / SCHEMBL16057166

SCHEMBL16057166

SCHEMBL16057166

O=C(O)NCC(=O)NNC(=O)C(F)(F)F

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ CA2 P00918 2/20 0.36
▸ CA3 P07451 2/20 0.35
▸ CA5A P35218 2/20 0.35
▸ CA5B Q9Y2D0 2/20 0.35
▸ CA12 O43570 1/20 0.35
▸ CA4 P22748 1/20 0.35
▸ CA6 P23280 1/20 0.35
▸ CA7 P43166 1/20 0.35
▸ CA9 Q16790 1/20 0.35
▸ CA14 Q9ULX7 1/20 0.35
▸ EPHX1 P07099 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28843017 0.78 ALDH1A1 (0.54) ALDH1A1POLBSMN1; SMN2MEN1KMT2A
SCHEMBL16082152 0.74 APLNR (0.44) ALDH1A1POLBSMN1; SMN2MEN1KMT2A
SCHEMBL23148225 0.74 CA2 (0.48) ALDH1A1POLBSMN1; SMN2MEN1KMT2A
SCHEMBL2884635 0.74 CA2 (0.59) ALDH1A1POLBSMN1; SMN2MEN1KMT2A
SCHEMBL6940463 0.71 CYP2C19 (0.36) ALDH1A1SMN1; SMN2KMT2A
SCHEMBL726450 0.71 ALDH1A1 (0.44) ALDH1A1POLBSMN1; SMN2MEN1KMT2A
SCHEMBL1289956 0.70 LMNA (0.40) ALDH1A1POLBSMN1; SMN2MEN1KMT2A
SCHEMBL20637975 0.69 ALDH1A1 (0.39) ALDH1A1POLBSMN1; SMN2MEN1KMT2A
SCHEMBL11895560 0.69 ALDH1A1 (0.65) ALDH1A1POLBSMN1; SMN2MEN1KMT2A
SCHEMBL15034385 0.68 ALDH1A1 (0.46) ALDH1A1POLBSMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3998260-B1 SGC STIMULATORS CYCLERION THERAPEUTICS INC (US) 2023-11-01 — — EP disclosed
WO-2023192989-A2 PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS AZKARRA THERAPEUTICS, INC. (US) 2023-10-05 — — WO disclosed
US-20230106002-A1 sGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. 2023-04-06 — — US disclosed
EP-3998260-A1 SGC STIMULATORS Cyclerion Therapeutics, Inc. (US) 2022-05-18 — — EP disclosed
EP-3660013-B1 SGC STIMULATORS CYCLERION THERAPEUTICS INC (US) 2022-01-19 — — EP disclosed
US-11207323-B2 sGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2021-12-28 — — US disclosed
US-20200316065-A1 sGC STIMULATORS CYCLERION THERAPEUTICS, INC. 2020-10-08 — — US disclosed
EP-3660013-A1 SGC STIMULATORS Cyclerion Therapeutics, Inc. (US) 2020-06-03 — — EP disclosed
US-10639308-B2 sGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2020-05-05 — — US disclosed
US-20190167679-A1 sGC STIMULATORS CYCLERION THERAPEUTICS, INC. 2019-06-06 — — US disclosed
US-10183021-B2 sGC stimulators IRONWOOD PHARMACEUTICALS, INC. (US) 2019-01-22 — — US disclosed
US-20170137439-A1 sGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2017-05-18 — — US disclosed
US-20170136019-A1 sGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2017-05-18 — — US disclosed
US-9586937-B2 sGC stimulators IRONWOOD PHARMACEUTICALS, INC. (US) 2017-03-07 — — US disclosed
US-20160375022-A1 sGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2016-12-29 — — US disclosed
US-20160347738-A1 sGC STIMULATORS CYCLERION THERAPEUTICS, INC. 2016-12-01 — — US disclosed
US-9481689-B2 sGC stimulators IRONWOOD PHARMACEUTICALS, INC. (US) 2016-11-01 — — US disclosed
US-20160031903-A1 sGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2016-02-04 — — US disclosed
EP-2970243-A2 SGC STIMULATORS Ironwood Pharmaceuticals, Inc. (US) 2016-01-20 — — EP disclosed
WO-2014144100-A2 SGC STIMULATORS NAKAI TAKASHI (US) 2014-09-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230106002-A1 sGC STIMULATORS PTGIS, CGAS, GUCY1A1 ALDH1A1 1529/4885POLB 2322/4885SMN1; SMN2 1246/4885
US-20170137439-A1 sGC STIMULATORS PTGIS, CGAS, GUCY1A1 ALDH1A1 1529/4885POLB 2322/4885SMN1; SMN2 1246/4885
US-11207323-B2 sGC stimulators PTGIS, CGAS, GUCY1A1 ALDH1A1 1529/4885POLB 2322/4885SMN1; SMN2 1246/4885
US-10639308-B2 sGC stimulators PTGIS, CGAS, GUCY1A1 ALDH1A1 1529/4885POLB 2322/4885SMN1; SMN2 1246/4885
US-20160347738-A1 sGC STIMULATORS PTGIS, CGAS, GUCY1A1 ALDH1A1 1529/4885POLB 2322/4885SMN1; SMN2 1246/4885
US-10183021-B2 sGC stimulators PTGIS, CGAS, GUCY1A1 ALDH1A1 1529/4885POLB 2322/4885SMN1; SMN2 1246/4885
US-20170136019-A1 sGC STIMULATORS PTGIS, CGAS, GUCY1A1 ALDH1A1 1529/4885POLB 2322/4885SMN1; SMN2 1246/4885
US-20160375022-A1 sGC STIMULATORS PTGIS, CGAS, GUCY1A1 ALDH1A1 1529/4885POLB 2322/4885SMN1; SMN2 1246/4885
US-20190167679-A1 sGC STIMULATORS PTGIS, CGAS, GUCY1A1 ALDH1A1 1529/4885POLB 2322/4885SMN1; SMN2 1246/4885
US-20160031903-A1 sGC STIMULATORS PTGIS, CGAS, GUCY1A1 ALDH1A1 1529/4885POLB 2322/4885SMN1; SMN2 1246/4885
US-20200316065-A1 sGC STIMULATORS PTGIS, CGAS, GUCY1A1 ALDH1A1 1529/4885POLB 2322/4885SMN1; SMN2 1246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.